Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Imvotamab by IGM Biosciences for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Imvotamab is under clinical development by IGM Biosciences and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
Imvotamab by IGM Biosciences for Follicular Lymphoma: Likelihood of Approval
Imvotamab is under clinical development by IGM Biosciences and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
Imvotamab by IGM Biosciences for Non-Hodgkin Lymphoma: Likelihood of Approval
Imvotamab is under clinical development by IGM Biosciences and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase...
Imvotamab by IGM Biosciences for Rheumatoid Arthritis: Likelihood of Approval
Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase...
Imvotamab by IGM Biosciences for Systemic Lupus Erythematosus: Likelihood of Approval
Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData,...
Imvotamab by IGM Biosciences for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Imvotamab is under clinical development by IGM Biosciences and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...
Imvotamab by IGM Biosciences for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Imvotamab is under clinical development by IGM Biosciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...